tiprankstipranks
Trending News
More News >

Ovid Therapeutics Sells Ganaxolone Royalties to Immedica

Story Highlights
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica

Don’t Miss TipRanks’ Half-Year Sale

Ovid Therapeutics ( (OVID) ) has provided an announcement.

On June 23, 2025, Ovid Therapeutics entered into an agreement with Immedica Pharma AB to sell its future royalties related to ganaxolone, a medicine used for treating CDKL5 deficiency disorder, for $7.0 million. This transaction provides Ovid with non-dilutive funding to support its operations, while Immedica gains control over ganaxolone’s intellectual property rights, enhancing its focus on rare diseases.

The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.

Spark’s Take on OVID Stock

According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.

Ovid Therapeutics’ stock score is primarily impacted by financial performance challenges including revenue inconsistency and profitability issues. Technical analysis indicates a bearish trend with no immediate signs of recovery. Valuation metrics further reflect financial instability. The lack of earnings call data and notable corporate events leaves these areas unaddressed.

To see Spark’s full report on OVID stock, click here.

More about Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs. The company is advancing a pipeline of novel, targeted small molecule candidates for neurological and neuropsychiatric disorders, including treatment-resistant seizures and other CNS disorders.

Average Trading Volume: 628,762

Technical Sentiment Signal: Sell

Current Market Cap: $21.45M

For detailed information about OVID stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1